Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GILEAD SCIENCES | 60,63 | -3,30 % | Virushepatitis bis 2030 eliminieren: Gilead Sciences fördert zahlreiche Projekte weltweit mit 4 Millionen US-Dollar - auch in Deutschland | Martinsried bei München (ots) - - Gilead vergibt 4 Millionen US-Dollar weltweit (ohne die Vereinigten Staaten) durch das Förderprogramm "ALL4LIVER Grant" -- Die World Hepatitis Alliance und hochrangige... ► Artikel lesen | |
INCYTE | 47,300 | -2,17 % | Medikament des Jahres - Auszeichnung für Incyte | München (ots) - Das bundesweite Netzwerk spezialisierter und innovativer Dermatologen, onkoderm e. V., hat auf der diesjährigen DERM Frankenthal, der größten Fachtagung für niedergelassene Hautärzte... ► Artikel lesen | |
ZOETIS | 143,30 | +1,63 % | Dividendenbekanntmachungen (18.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABSA GROUP LIMITED ADR US00400T1025 0,5706 USD 0,5347 EUR AKER ASA NO0010234552 15,5 NOK 1,3202 EUR ANORA GROUP OYJ FI4000292438 - 0... ► Artikel lesen | |
AMARIN | 0,820 | -0,61 % | Amarin Corporation plc: Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event | DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration... ► Artikel lesen | |
CASSAVA SCIENCES | 19,995 | +3,20 % | Cassava Sciences, Inc.: Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials | An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials... ► Artikel lesen | |
ACHIEVE LIFE SCIENCES | 4,115 | +0,73 % | Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 | ||
LIGAND PHARMACEUTICALS | 66,00 | -0,75 % | LIGAND PHARMACEUTICALS INC - 8-K, Current Report | ||
MADRIGAL PHARMACEUTICALS | 181,35 | -5,10 % | Madrigal Pharmaceuticals, Inc.: Madrigal Statement on the Passing of Dr. Stephen Harrison | ||
SEELOS THERAPEUTICS | 1,060 | -100,00 % | Seelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpoints | WASHINGTON (dpa-AFX) - Seelos Therapeutics, Inc. (SEEL) issued an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. The study was designed to evaluate SLS-005 in decreasing... ► Artikel lesen | |
ENZON PHARMACEUTICALS | 0,056 | -3,45 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.11.2023 | The following instruments on Boerse Frankfurt do have their last trading day on 17.11.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.11.2023ISIN NameAU000000DCN6 DACIAN... ► Artikel lesen | |
TALPHERA | 0,883 | +1,38 % | TALPHERA, INC. - 8-K, Current Report | ||
ANI PHARMACEUTICALS | 60,50 | 0,00 % | Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts | ||
RIGEL PHARMACEUTICALS | 1,031 | -2,00 % | Rigel Pharmaceuticals, Inc.: Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan,... ► Artikel lesen | |
MOLECULAR TEMPLATES | 1,590 | -3,05 % | Molecular Templates, Inc.: Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced | AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular Templates," or "MTEM"), a clinical-stage biopharmaceutical company focused on the discovery and... ► Artikel lesen | |
SAVARA | 3,840 | -3,03 % | Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update | LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth... ► Artikel lesen |